Biology-driven therapy advances in high-grade serous ovarian cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• High-grade serous ovarian cancer (HGSOC) research faced slow progress until genome sequencing and revised understanding of its cellular origin. This led to new perspectives on HGSOC biology and treatment strategies.
• Key discoveries include VEGF-driven angiogenesis and homologous recombination deficiency as critical drivers and therapeutic targets in ovarian tumorigenesis.

Purpose of the Study:

• To review recent advances in understanding HGSOC biology and treatment.
• To highlight the impact of new molecular insights and therapeutic agents, such as PARP inhibitors (PARPis), on HGSOC management.
• To discuss current challenges and future directions in ovarian cancer research.

Main Methods:

• Review of recent scientific literature and experimental findings in ovarian cancer research.
• Analysis of molecular profiling data for different ovarian cancer subtypes.
• Examination of clinical trial outcomes for novel therapeutic agents.

Main Results:

• Genome sequencing and cell-of-origin insights have reshaped the understanding of HGSOC.
• Discovery of key pathways like VEGF-driven angiogenesis and homologous recombination deficiency.
• Molecular subtyping has enabled initial personalized treatment approaches.
• PARP inhibitors (PARPis) have demonstrated significant clinical benefit in specific HGSOC patient subsets.
• Research into PARPis resistance is revealing new vulnerabilities and treatment avenues.

Conclusions:

• Advances in genomics and molecular biology have significantly improved the outlook for high-grade serous ovarian cancer.
• PARP inhibitors represent a major therapeutic breakthrough for selected patients, with ongoing research addressing resistance.
• Personalized treatment strategies based on molecular profiling are becoming increasingly important in managing ovarian cancer.